Prognostic Factors Influencing the Efficacy of Regorafenib in the Treatment of Metastatic Colorectal Cancer

Aim: Metastatic colorectal cancer (mCRC) remains a significant clinical challenge for patients who have exhausted standard treatment options. Regorafenib, an oral multikinase inhibitor, is approved for use in refractory with mCRC patients; however, its real-world efficacy continues to be an area of...

Full description

Bibliographic Details
Published in:	Namık Kemal Tıp Dergisi
Main Authors:	Nadiye SEVER, İbrahim Vedat BAYOĞLU
Format:	Article
Language:	English
Published:	Tekirdağ Namık Kemal University 2025-06-01
Subjects:	regorafenib metastatic colorectal cancer survival
Online Access:	https://namikkemalmedj.com/articles/prognostic-factors-influencing-the-efficacy-of-regorafenib-in-the-treatment-of-metastatic-colorectal-cancer/doi/nkmj.galenos.2025.34654

Similar Items

The efficacy of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer: a retrospective study
by: An Tianqi, et al.
Published: (2022-08-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
by: Emaan Haque, et al.
Published: (2022-12-01)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
by: Sabin Goktas Aydin, et al.
Published: (2023-11-01)

Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
by: Zhong J, et al.
Published: (2024-06-01)

Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital
by: Pilar Sotoca Rubio, et al.
Published: (2024-11-01)

Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data
by: Tanios Bekaii-Saab, et al.
Published: (2024-08-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
by: Oronzo Brunetti, et al.
Published: (2019-12-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Digital patient modeling identifies predictive biomarkers of regorafenib response in elderly metastatic colorectal cancer
by: Juan Manuel García-Illarramendi, et al.
Published: (2025-09-01)

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
by: Wang Qu, et al.
Published: (2024-01-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
by: Simona De Summa, et al.
Published: (2021-11-01)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
by: Ya-Ya Deng, et al.
Published: (2023-03-01)

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT)
by: Shujuan Zhou, et al.
Published: (2023-10-01)

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context
by: Marwan Fakih, et al.
Published: (2023-04-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)

Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study
by: T.-C. Wu, et al.
Published: (2024-06-01)

Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)
by: Tanios Bekaii-Saab, et al.
Published: (2025-06-01)

NEW POSSIBILITIES OF THERAPY OF INTENSIVELY PRETREATED METASTATIC COLORECTAL CANCER PATIENTS
by: E. V. ARTAMONOVA
Published: (2016-12-01)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
by: Puthiamadathil JM, et al.
Published: (2017-10-01)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
by: Federica Martorana, et al.
Published: (2017-11-01)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
by: Tao Yuan, et al.
Published: (2023-04-01)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
by: Beibei Chen, et al.
Published: (2022-12-01)

Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
by: Prachi Bajpai, et al.
Published: (2024-07-01)

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types
by: Hofheinz RD, et al.
Published: (2021-07-01)

Is the Combination of Pembrolizumab and Regorafenib the Beginning of a New Era in the Treatment of Metastatic Colorectal Cancer?
by: Aslı GEÇGEL, et al.
Published: (2025-08-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis
by: Yuanhang Han, et al.
Published: (2025-02-01)

Research progress of regorafenib in the treatment of colorectal cancer
by: CHEN Yixuan, et al.
Published: (2024-09-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer
by: Wen‐Zhuo He, et al.
Published: (2023-03-01)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
by: Marie-Laure Amram, et al.
Published: (2017-11-01)

Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review
by: Abdullah Esmail, et al.
Published: (2025-04-01)

Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study
by: Masayuki Nakashima, et al.
Published: (2023-12-01)

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
by: Goel G
Published: (2018-03-01)